Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of BNTC is 24 and suggests 91% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell